You just read:

Portola Presents New Interim Data on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma

News provided by

Portola Pharmaceuticals, Inc.®

Jun 19, 2019, 12:48 ET